Published in J Biol Chem on July 01, 2004
Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00
Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood (2010) 1.67
The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol (2007) 1.46
Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis. J Biol Chem (2009) 1.37
Development of the mammalian lymphatic vasculature. J Clin Invest (2014) 1.34
Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol (2010) 1.08
Platelets: covert regulators of lymphatic development. Arterioscler Thromb Vasc Biol (2010) 1.06
Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Exp Cell Res (2009) 1.00
Platelet aggregation in the formation of tumor metastasis. Proc Jpn Acad Ser B Phys Biol Sci (2008) 1.00
A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep (2014) 0.97
Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin. Acta Histochem Cytochem (2012) 0.86
Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch (2007) 0.85
Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets. Blood (2014) 0.84
Genome-wide two-locus epistasis scans in prostate cancer using two European populations. Hum Genet (2012) 0.84
Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2. Retrovirology (2010) 0.83
Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother (2015) 0.81
Podoplanin - a small glycoprotein with many faces. Am J Cancer Res (2016) 0.81
LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin. PLoS One (2016) 0.80
Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget (2016) 0.80
Mucin-type O-glycosylation is critical for vascular integrity. Glycobiology (2014) 0.77
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med (2017) 0.76
Podoplanin-mediated TGF-β-induced epithelial-mesenchymal transition and its correlation with bHLH transcription factor DEC in TE-11 cells. Int J Oncol (2016) 0.76
Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med (2017) 0.75
Morphological study of tooth development in podoplanin-deficient mice. PLoS One (2017) 0.75
Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity. J Biol Chem (2014) 0.75
Expression of podoplanin and prognosis in oropharyngeal cancer. Eur Arch Otorhinolaryngol (2014) 0.75
WoLF PSORT: protein localization predictor. Nucleic Acids Res (2007) 10.14
Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res (2002) 3.01
Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol (2004) 2.63
Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem (2007) 2.44
Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow. J Cell Biol (2003) 2.40
Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst (2004) 2.30
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res (2008) 2.20
Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem (2002) 2.17
Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res (2003) 2.04
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell (2005) 1.96
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther (2002) 1.95
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci (2003) 1.86
Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell (2005) 1.82
Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res (2005) 1.76
Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (2006) 1.70
Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem (2003) 1.67
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res (2005) 1.65
Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci (2007) 1.64
Pulmonary hemorrhage associated with Henoch-Schönlein purpura in a child. Clin Rheumatol (2008) 1.64
Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem (2003) 1.59
Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res (2004) 1.58
Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol Cell Biol (2005) 1.56
Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem (2002) 1.55
Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res (2009) 1.53
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A (2004) 1.49
SOX9 expression and its methylation status in gastric cancer. Virchows Arch (2012) 1.47
A common variation in EDAR is a genetic determinant of shovel-shaped incisors. Am J Hum Genet (2009) 1.47
The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol (2007) 1.46
Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol (2005) 1.45
Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene (2002) 1.42
Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol (2007) 1.39
Two universal primer sets for species identification among vertebrates. Int J Legal Med (2006) 1.35
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet (2004) 1.35
Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol (2011) 1.31
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer (2002) 1.29
Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem (2004) 1.29
Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene (2005) 1.27
Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene (2006) 1.26
Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem (2002) 1.26
Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol (2003) 1.26
Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res (2004) 1.25
Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res (2003) 1.24
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst (2005) 1.23
B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. Apoptosis (2008) 1.22
Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene (2004) 1.20
Insulin-stimulated interaction with 14-3-3 promotes cytoplasmic localization of lipin-1 in adipocytes. J Biol Chem (2009) 1.19
Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun (2006) 1.19
Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification. Mol Cell Proteomics (2008) 1.16
Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement. J Cell Biol (2009) 1.15
Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch (2006) 1.15
Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther (2002) 1.13
Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1. J Cell Biochem (2009) 1.13
Freud-1/Aki1, a novel PDK1-interacting protein, functions as a scaffold to activate the PDK1/Akt pathway in epidermal growth factor signaling. Mol Cell Biol (2008) 1.13
Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J Biol Chem (2002) 1.13
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res (2009) 1.12
Human intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms. J Biol Chem (2004) 1.12
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol (2011) 1.12
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One (2013) 1.11
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol (2013) 1.11
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol (2013) 1.10
Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett (2007) 1.10
Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3. J Biol Chem (2002) 1.10
Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun (2008) 1.10
A novel beta(1,6)-N-acetylglucosaminyltransferase V (GnT-VB)(1). FEBS Lett (2003) 1.09
The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer (2012) 1.08
Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol (2008) 1.08
Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology (2009) 1.07
3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. J Biol Chem (2005) 1.07
Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res (2002) 1.07
ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch (2012) 1.06
Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol (2006) 1.06